Mechanistic insights into the antipruritic effects of lebrikizumab, an anti–IL-13 mAb

IL-13 is a potent enhancer of neuronal responses to different itch stimuli, consistent with the neuroimmune axis contributing to chronic itch-associated inflammatory skin disease, and blockade of this cytokine pathway may provide a therapeutic approach.